RAVENNA PHARMACEUTICALS INC has a total of 12 patent applications. Its first patent ever was published in 2018. It filed its patents most often in Australia, Brazil and EPO (European Patent Office). Its main competitors in its focus markets organic fine chemistry and pharmaceuticals are PETRA PHARMA CORP, HANGZHOU HUADONG MEDICINE GROUP BIOLOGY ENG RES CO LTD and MAGGIONI WINTHROP SPA.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 3 | |
#2 | Brazil | 3 | |
#3 | EPO (European Patent Office) | 3 | |
#4 | WIPO (World Intellectual Property Organization) | 2 | |
#5 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Organic fine chemistry | |
#2 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Heterocyclic compounds | |
#2 | Therapeutic chemical compounds | |
#3 | Special acyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Kesicki Edward A | 9 |
#2 | Gerasyuto Aleksey I | 7 |
#3 | Dahlgren Markus K | 7 |
#4 | Persson Lars Boukharta | 7 |
#5 | Lindström Johan | 7 |
#6 | Hickey Eugene R | 7 |
#7 | Viklund Jenny | 7 |
#8 | Forsblom Rickard | 5 |
#9 | Ginman Tobias | 5 |
#10 | Edward A Kesicki | 3 |
Publication | Filing date | Title |
---|---|---|
WO2020257271A1 | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | |
EP3728217A1 | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |